Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix
Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Aug 9, 2024: “Intranasal Delivery of Quillaja brasiliensis Saponin-Based Nanoadjuvants Improve Humoral Immune Response of Influenza Vaccine in Aged Mice”.
1 paper studies it2 findingsUpdated
See all 1 papers on trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Canada First Research Excellence Fund and 3 more
- Animals1
What did studies of trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix find?
2Studies of trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix measured 2 outcomes: influenza and immune response.
Influenza
downin mice1
1 study
Influenza
downin mice1
Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix protects against influenza in mice (H1N1pdm09-like virus challenge).
“Overall, TIV-IMXQB improved the immunogenicity compared to TIV by enhancing systemic and mucosal immunity in old mice conferring a faster recovery after the H1N1pdm09-like virus challenge.”
AnimalsH1N1pdm09-like virus challenge
Vaccines
Immune response
upin mice1
1 study
Immune response
upin mice1
Trivalent influenza vaccine + quillaja brasiliensis saponin-based iscom matrix activates immune response in mice.
“TIV-IMXQB improved the immunogenicity compared to TIV by enhancing systemic and mucosal immunity in old mice”
Animalsintranasal and subcutaneous
Vaccines